{"id":"W2050088310","doi":"10.1016/j.exphem.2013.05.205","title":"Effectively targeting treatment-naïve CML stem/progenitor cells from imatinib-nonresponders with combination treatments of new JAK2 and ABL inhibitors in vitro and in vivo","year":2013,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Dasatinib; Progenitor cell; Nilotinib; Stem cell; Imatinib; Pharmacology; Imatinib mesylate; CD34; Medicine; Cancer research; Bone marrow; In vivo; Tyrosine kinase; Tyrosine-kinase inhibitor; Immunology; Internal medicine; Biology; Receptor; Myeloid leukemia; Cell biology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002318073,0.0002493345,0.000407475,0.0002693923,0.0001607281,0.0003368643,0.0002143982,0.0001993937,0.002582179],"category_scores_gemma":[0.0001071113,0.0001585298,0.0001948711,0.0001544196,0.0001193808,0.0002275279,0.0001491289,0.0007757421,0.0004149631],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001142718,"about_ca_system_score_gemma":0.0002443404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003804818,"about_ca_topic_score_gemma":0.001300686,"domain_scores_codex":[0.9998819,0.00002170416,0.000007446731,0.00001965942,0.00003531019,0.00003408915],"domain_scores_gemma":[0.9999648,0.000009224585,0.000005258351,0.000005987801,0.000003168213,0.00001149804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002286153,0.0013608,0.0009040415,0.00009816913,0.00006760281,0.00007609036,0.00006042547,0.0008740608,0.9749237,0.0002758125,0.0007989433,0.01827415],"study_design_scores_gemma":[0.001925904,0.01947457,0.02239314,0.0000201529,0.000294313,0.001122806,0.0001324153,0.009314738,0.9353467,0.0002611373,0.009695106,0.00001908451],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966234,0.0008326579,0.0009167857,0.00008989892,0.00004024184,0.00009547657,0.0002105174,0.00003698741,0.001154014],"genre_scores_gemma":[0.9964323,0.0005314086,0.0009845444,0.00006012966,0.00002307794,0.00008593494,0.0005825377,0.000009685343,0.001290384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002582179,"threshold_uncertainty_score":0.008638322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01124780700506541,"score_gpt":0.2643041934187166,"score_spread":0.2530563864136512,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}